Radiation dose is elegantly defined as simply a measure of energy absorbed per unit mass. However, calculating the biological impact of radiation on humans can be complicated, as it depends on several factors. Currently, radiopharmaceutical trials are frequently stopped because of conventional dose limitations for organs at risk. However, it's becoming increasingly apparent that these limitations may be too conservative and unsuitable for radiopharmaceutical therapies. This just-published paper in JCO by Ana Kiess et al. highlights this issue. It presents solid recommendations for phase 1 clinical trials, which could be used to establish appropriate tolerances for organs at risk in radiopharmaceutical therapies. This is excellent work by the RTP-TEC group; they have additional important manuscripts in progress. ##teamwork #radiopharmaceuticals #RPT #theranostics Ana Kiess Joe O'Donoghue Carlos UribeLisa Bodei Adam Kesner George Sgouros Society of Nuclear Medicine and Molecular Imaging (SNMMI) European Association of Nuclear Medicine (EANM) American Society for Radiation Oncology American Association of Physicists in Medicine Oncidium foundation
External beam radiation and radioligand therapy are not the same. So why do we use EBRT tolerances to define MTDs in radioligand therapy? https://lnkd.in/dgNw3UNz (hint: we shouldn't) Fantastic and timely article by Ana Kiess, George Sgouros, Jacob Hesterman, Carlos Uribe, Rob Hobbs, Adam Kesner, Lisa Bodei, Joe O'Donoghue, and the rest of RPT-TEC on how #radiopharmaceuticals can reach their full potential. Congratulations Team!
